NYSE:LLYPharmaceuticals
Does Lilly’s Broad Pipeline Wins in Obesity and Immunology Reshape the Bull Case for LLY?
In late February 2026, Eli Lilly reported a series of product updates, including positive EMA guidance for Olumiant in adolescents with severe alopecia areata, strong Phase 3 data for oral GLP-1 candidate orforglipron versus oral semaglutide, label expansion for Zepbound’s monthly KwikPen, and durable multi-year results for Omvoh in inflammatory bowel disease.
These developments highlight how Lilly is broadening its cardiometabolic and immunology franchises beyond injectable GLP-1s,...